First, in DAPA-HF, the benefits of dapagliflozin on the progression of heart failure were seen to a similar extent in both patients with or without diabetes, thus undermining the hypothesis that mitigation of glycemia-related cardiotoxicity by SGLT2 inhibitors slows the progression of heart failure [5]. The gene discussed is SLC5A2; the disease is hydrops fetalis.